A deficiency in Mdm2 binding protein inhibits Myc-induced B-cell proliferation and lymphomagenesis

J Odvody1, T Vincent, M P Arrate

  • 1Department of Pathology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.

Oncogene
|March 23, 2010
PubMed

Insights

Mdm2 binding protein (MTBP) is a novel regulator of Myc-induced cancer. Reduced MTBP levels delay lymphoma formation by inhibiting cell proliferation, independent of the Mdm2/p53 pathway.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Mdm2 binding protein (MTBP) is linked to cell-cycle arrest and the Mdm2/p53 tumor suppressor pathway.
  • The oncogene c-Myc drives B-cell lymphomas via Mdm2/p53 pathway inactivation.

Purpose of the Study:

  • To investigate MTBP's function in tumorigenesis.
  • To determine MTBP's role in the Mdm2/p53 pathway and Myc-driven cancers.

Main Methods:

  • Crossed Mtbp-deficient mice with Emu-myc transgenic mice.
  • Analyzed B-cell lymphoma development, apoptosis, Mdm2 levels, and Myc target gene expression.

Main Results:

  • Myc-induced B-cell lymphoma development was significantly delayed in Mtbp heterozygous mice.
  • Reduced MTBP did not affect B-cell apoptosis or Mdm2 levels.
  • Mtbp deficiency inhibited Myc-induced proliferation and upregulation of Myc target genes.
  • MTBP expression is induced by Myc and elevated in lymphomas.

Conclusions:

  • MTBP functions independently of Mdm2 in tumorigenesis.
  • MTBP is a limiting factor for Myc's proliferative and transforming functions.
  • MTBP is a previously unrecognized regulator of Myc-induced tumorigenesis.

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic cells are...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...